Biotechnology News and Research

RSS

Researchers suggest new strategy to control cellular identity and fate

A team of scientists that included researchers from UCLA has discovered a novel mechanism of RNA regulation in embryonic stem cells. The findings are strong evidence that a specific chemical modification, or "tag," on RNA plays a key role in determining the ability of embryonic stem cells to adopt different cellular identities.

6 Dec 2014

Cellular Research announces commercial availability of Precise targeted RNASeq assays

Cellular Research today announced the commercial launch of its Precise targeted RNASeq assays. The company also announced the commercial availability of application-focused panels for the Precise assays, including panels designed for oncology, induced pluripotent stem cells and immunology.

5 Dec 2014

Isis Pharmaceuticals CEO honored with SCRIP Lifetime Achievement Award

Stanley T. Crooke, Ph.D., M.D., founder, CEO and chairman of the board of directors of Isis Pharmaceuticals, Inc., has been awarded the 2014 SCRIP Lifetime Achievement Award, one of the most prestigious of its kind in the pharmaceutical and biotechnology industries worldwide.

5 Dec 2014

Breakthrough research could lead to prosthetic retinas for people suffering from retinal damage

Scientists have developed a new light-sensitive film that could one day form the basis of a prosthetic retina to help people suffering from retinal damage or degeneration. Hebrew University of Jerusalem researchers collaborated with colleagues from Tel Aviv University and Newcastle University in the research, which was published in the journal Nano Letters.

5 Dec 2014

Phase IIb trial shows platinum-resistant ovarian patients treated with PM1183 live longer

Zeltia announces today that its pharmaceutical division PharmaMar has data from a group of 33 randomized patients with platinum-resistant ovarian cancer demonstrating that PM1183 shows a significantly superior median overall survival compared to topotecan.

4 Dec 2014

New collaborative project aims to generate 3% productivity boost at Australian pharmaceutical sites

META, a collaborative network of high potential manufacturing businesses and researchers, has today announced a collaborative project between Hospira, GlaxoSmithKline and CSL to generate a targeted 3% productivity boost with an estimated return on investment of up to $2.4M dollars at Australian pharmaceutical sites.

4 Dec 2014

$TxCell enrolls first patient in Ovasave phase IIb trial for treatment of refractory Crohn’s disease$

TxCell enrolls first patient in Ovasave phase IIb trial for treatment of refractory Crohn’s disease

TxCell SA, a biotechnology company developing novel and innovative, cost-effective personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that it has enrolled the first patient in its phase IIb clinical trial of its lead product Ovasave in refractory Crohn’s disease.

4 Dec 2014

Scientists develop system for printing protein patterns onto film

Protein-coated Petri dishes are increasingly being used to support cell growth during cell cultivation. Scientists have developed a system for printing protein patterns onto film using a roll-to-roll process, which allows high volumes to be manufactured efficiently and cost-effectively.

3 Dec 2014

New study describes revolutionary novel device that has potential to treat eye diseases

The aging process affects everything from cardiovascular function to memory to sexuality. Most worrisome for many, however, is the potential loss of eyesight due to retinal degeneration.

3 Dec 2014

Unique challenges in providing psychotherapy to people with ASD and gender dysphoria

The challenges in providing psychotherapy to individuals with autism spectrum disorders (ASD) who also are struggling with their gender identity are explored in two case studies of high-functioning persons with diagnoses of ASD and gender dysphoria (GD).

3 Dec 2014

Vital Therapies to use Veeva Vault applications to share clinical information

With an investigational combination biological product in Phase III clinical trials and a recent IPO, Vital Therapies, Inc. is readying its clinical and regulatory operations for global collaboration and greater efficiency with cloud-based Veeva Vault eTMF and Veeva Vault Submissions content management applications from Veeva Systems.

3 Dec 2014

Ceres to develop new method for detecting the presence of Ebola virus in saliva

Ceres Nanosciences Inc. today announced the commencement of a development program, funded by the Gates Foundation, to use Ceres' Nanotrap particle technology to develop a new method of detecting the presence of the Ebola virus in saliva.

3 Dec 2014

Monash University, 60P Australia partner to develop Fenretinide drug for dengue fever

Monash University and 60P Australia Pty Ltd, a subsidiary of 60° Pharmaceuticals LLC, have announced today an exclusive partnering deal, with 60P obtaining rights to develop the drug Fenretinide for dengue fever.

2 Dec 2014

BioPharmX submits request for pre-IND meeting to FDA for topical antibiotic acne compound

BioPharmX Corporation, a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced that it has submitted a request for a pre-IND (Investigational New Drug) meeting to the U.S. Food and Drug Administration for the company's topical antibiotic acne compound currently under development.

2 Dec 2014

Oncolytics Biotech submits Orphan Drug Designation for pancreatic, ovarian cancers

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) today announced that it has submitted applications for Orphan Drug Designation to the U.S. Food and Drug Administration ("FDA") for REOLYSIN® for the treatment of pancreatic and ovarian cancers.

2 Dec 2014

AYOXXA Biosystems closes third round of Series B financing

AYOXXA Biosystems GmbH, an international biotechnology company, announces the closing of a third round of Series B financing, bringing the total amount raised to 11.3 Mio. EUR in 2014.

2 Dec 2014

Apellis Pharmaceuticals completes $33M private placement of Series C Preferred Stock

Apellis Pharmaceuticals, Inc., a leading biotechnology company applying immunotherapy to autoimmune disease, today announced that it has completed a $33M private placement of its Series C Preferred Stock.

2 Dec 2014

Findings could help researchers understand mechanisms involved in ageing

A study from the University of Exeter has found that male flies die earlier than their female counterparts when forced to evolve with the pressures of mate competition and juvenile survival. The results could help researchers understand the mechanisms involved in ageing.

1 Dec 2014

Baxter seeks FDA approval of BAX 855 for treatment of people with hemophilia A

Nektar Therapeutics reported that partner Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) to the United States Food and Drug Administration for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].

From Baxter International Inc. 1 Dec 2014

New book explores convergence as key to stable global agricultural platform

A scientific text, Convergence of Food Security, Energy Security and Sustainable Agriculture, is now available through Springer Science+Business Media.

1 Dec 2014

Biotechnology News and Research

Researchers suggest new strategy to control cellular identity and fate

Cellular Research announces commercial availability of Precise targeted RNASeq assays

Isis Pharmaceuticals CEO honored with SCRIP Lifetime Achievement Award

Breakthrough research could lead to prosthetic retinas for people suffering from retinal damage

Phase IIb trial shows platinum-resistant ovarian patients treated with PM1183 live longer

New collaborative project aims to generate 3% productivity boost at Australian pharmaceutical sites

TxCell enrolls first patient in Ovasave phase IIb trial for treatment of refractory Crohn’s disease

Scientists develop system for printing protein patterns onto film

New study describes revolutionary novel device that has potential to treat eye diseases

Unique challenges in providing psychotherapy to people with ASD and gender dysphoria

Vital Therapies to use Veeva Vault applications to share clinical information

Ceres to develop new method for detecting the presence of Ebola virus in saliva

Monash University, 60P Australia partner to develop Fenretinide drug for dengue fever

BioPharmX submits request for pre-IND meeting to FDA for topical antibiotic acne compound

Oncolytics Biotech submits Orphan Drug Designation for pancreatic, ovarian cancers

AYOXXA Biosystems closes third round of Series B financing

Apellis Pharmaceuticals completes $33M private placement of Series C Preferred Stock

Findings could help researchers understand mechanisms involved in ageing

Baxter seeks FDA approval of BAX 855 for treatment of people with hemophilia A

New book explores convergence as key to stable global agricultural platform

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News